Catalent (NYSE:CTLT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday.
According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
A number of other equities analysts also recently issued reports on CTLT. Wells Fargo & Co upped their price target on Catalent from $39.00 to $43.00 and gave the company an “outperform” rating in a report on Wednesday, September 20th. Bank of America reaffirmed a “buy” rating and issued a $45.00 price target (up from $40.00) on shares of Catalent in a report on Wednesday, September 20th. Morgan Stanley raised Catalent from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $29.00 to $48.00 in a report on Thursday, September 21st. ValuEngine downgraded Catalent from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. Finally, BidaskClub raised Catalent from a “hold” rating to a “buy” rating in a report on Thursday, October 5th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $44.44.
Catalent (CTLT) opened at $42.94 on Thursday. The company has a quick ratio of 2.49, a current ratio of 2.91 and a debt-to-equity ratio of 2.01. The stock has a market capitalization of $5,650.00, a P/E ratio of 49.93, a P/E/G ratio of 2.73 and a beta of 1.41. Catalent has a fifty-two week low of $25.72 and a fifty-two week high of $43.42.
Catalent (NYSE:CTLT) last announced its quarterly earnings results on Monday, November 6th. The company reported $0.21 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.01. The firm had revenue of $543.90 million during the quarter, compared to the consensus estimate of $490.75 million. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The firm’s quarterly revenue was up 23.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.16 earnings per share. equities analysts anticipate that Catalent will post 1.47 EPS for the current fiscal year.
In other news, Director Uwe Roehrhoff acquired 7,500 shares of Catalent stock in a transaction on Tuesday, November 21st. The stock was bought at an average price of $39.22 per share, for a total transaction of $294,150.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John R. Chiminski sold 181,458 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total value of $7,189,365.96. The disclosure for this sale can be found here. 1.70% of the stock is currently owned by insiders.
Institutional investors have recently added to or reduced their stakes in the company. Zions Bancorporation purchased a new stake in shares of Catalent during the third quarter worth approximately $100,000. Acrospire Investment Management LLC raised its stake in shares of Catalent by 72.2% during the second quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock worth $109,000 after purchasing an additional 1,300 shares during the last quarter. Quantbot Technologies LP raised its stake in shares of Catalent by 110.7% during the second quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock worth $120,000 after purchasing an additional 1,804 shares during the last quarter. First Bank & Trust raised its stake in shares of Catalent by 54.2% during the fourth quarter. First Bank & Trust now owns 3,764 shares of the company’s stock worth $155,000 after purchasing an additional 1,323 shares during the last quarter. Finally, Fortaleza Asset Management Inc. purchased a new stake in shares of Catalent during the third quarter worth approximately $164,000. Institutional investors and hedge funds own 99.37% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://ledgergazette.com/2018/01/20/zacks-investment-research-downgrades-catalent-ctlt-to-hold.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.